Physician profile
Sanjay Cherukuri
NPI 1235394479
$131,557.98
in general payments reported to CMS, 2019-2025
31 companies · $3,881 in 2025
The $3,881 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,356 · 2020: $2,968 · 2021: $31K · 2022: $44K · 2023: $8,001 · 2024: $39K · 2025: $3,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Honoraria: $10K · Food and Beverage: $7,737 · Travel and Lodging: $5,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,115.00 |
| Honoraria | $10,165.00 |
| Food and Beverage | $7,737.49 |
| Travel and Lodging | $5,972.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $108,433.08 | 2019-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $13,674.57 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $2,922.62 | 2019-2025 | Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,736.66 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $638.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $557.70 | 2019-2025 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.12 | 2019-2025 | Jardiance |
| Abbott Laboratories | $522.35 | 2019-2025 | Esprit, Perclose Prostyle, Triclip |
| Inari Medical, INC. | $408.05 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $308.21 | 2019-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $262.76 | 2024-2025 | |
| Stryker Corporation | $252.01 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Flowtriever |
| Cequr Corporation | $198.35 | 2025 | Cequr Simplicity |
| Irhythm Technologies, INC. | $164.11 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Bridgebio Pharma, INC. | $155.36 | 2025 | Attruby |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $130.89 | 2025 | |
| Pfizer INC. | $123.94 | 2023-2025 | |
| Angiodynamics, INC. | $88.76 | 2025 | Auryon Laser System 100-120 Vac |
| Philips North America LLC | $69.66 | 2022-2024 | (P88) Igt Devices Fm |
| Amgen INC. | $54.61 | 2019-2025 | Repatha |
| W. L. Gore & Associates, INC. | $50.76 | 2020 | |
| Merck Sharp & Dohme LLC | $43.06 | 2023-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $42.43 | 2025 | |
| United Therapeutics Corporation | $37.42 | 2025 | |
| Medtronic, INC. | $27.44 | 2025 | Venaseal |
| Bard Peripheral Vascular, INC. | $25.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.21 | 2021 | |
| Terumo Medical Corporation | $21.34 | 2024 | Metacross Otw, Angio-Seal, Glidewire |
| Amarin Pharma, INC. | $16.98 | 2021 | |
| Cashflow Solutions, LLC | $14.35 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Kiniksa Pharmaceuticals, LTD. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Cherukuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.